Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.
2.

Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T.

J Diabetes Sci Technol. 2009 Nov 1;3(6):1442-50.

3.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
5.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
6.
7.
8.

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

J Clin Pharm Ther. 2010 Oct;35(5):565-79. doi: 10.1111/j.1365-2710.2009.01132.x.

PMID:
20831680
9.
10.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
11.

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T.

Diabet Med. 2005 Aug;22(8):980-5.

PMID:
16026361
12.

A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.

Diabetes Technol Ther. 2013 Mar;15(3):214-22. doi: 10.1089/dia.2012.0272. Epub 2013 Feb 21.

PMID:
23427864
13.
14.

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.

Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S.

J Intern Med. 2006 Aug;260(2):125-33.

15.

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R.

Hypertens Res. 2007 May;30(5):387-94.

PMID:
17587750
16.
17.

[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].

Rodríguez A, Reviriego J, Polavieja P, Mesa J.

Med Clin (Barc). 2008 Nov 29;131(19):721-30. Spanish.

PMID:
19091199
18.

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

Seufert J, Urquhart R.

Diabetes Res Clin Pract. 2008 Mar;79(3):453-60. Epub 2007 Dec 26.

PMID:
18160120
19.

Heat shock protein-70 and hypoxia inducible factor-1α in type 2 diabetes mellitus patients complicated with retinopathy.

Sayed KM, Mahmoud AA.

Acta Ophthalmol. 2016 Aug;94(5):e361-6. doi: 10.1111/aos.12919. Epub 2016 Jan 4.

20.

Supplemental Content

Support Center